Quibim Extends Into US Market With FDA Authorization Of QP-Prostate CAD

AI Radiology Tool For Prostate Cancer Lesion Detection

The US FDA's clearance of QP-Prostate CAD positions the company to support US health care providers and growing markets for fusion biopsy and focal therapy, said Quibim CEO and founder Angel Alberich-Bayarri.

prostate cancer imaging
(Shutterstock)

Quibim, a health tech startup designing AI tools to unlock clinical imaging data, received US Food and Drug Administration authorization for its QP-Prostate computer-aided detection (CAD) solution for the detection of prostate cancer lesions on MRI scans on 19 March.

“Integrating AI technology into prostate MRI enhances diagnostic precision in identifying clinically significant prostate cancer,” said Angel Alberich-Bayarri, CEO and...

More from Approvals

More from Startups & SMEs

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

UK Center To Develop Brain Stimulation Devices Opens

 

Backed by £50m of UK government funding, the new research center will delve into neural dynamics to develop novel devices ranging from brain implants to wearables.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.